Drugs / EDG-7500
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials · 1 met primary | ||||||
| Phase 1 | NCT07456059 | Mar → Jun 2026 overdue | — | Edgewise Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07324616 | Jan → May 2026 overdue | — | Edgewise Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07034768 | Jul → Dec 2025 | impaired renal function disease | Edgewise Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06738836 | Dec 2024 → Jan 2025 | — | Edgewise Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06011317 | Aug 2023 → May 2024 | — | Edgewise Therapeutics, Inc. | Completed | Met primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06347159 | Apr 2024 → Jun 2026 overdue | hypertrophic cardiomyopathy | Edgewise Therapeutics, Inc. | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-16 | Edgewise Therapeutics, Inc. | Results Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) edgewisetx.com ↗
today announced positive top-line results from the 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 in obstructive (oHCM) and nonobstructive (nHCM) HCM. |
| 2025-12-24 | Edgewise Therapeutics, Inc. | Results Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy edgewisetx.com ↗
In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF <50% – |
| 2025-04-02 | Edgewise Therapeutics, Inc. | Results Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) edgewisetx.com ↗
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM. |
| 2024-09-19 | Edgewise Therapeutics, Inc. | Results Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) edgewisetx.com ↗
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDG-7500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07456059 ↗ |
| Route | Oral | “EDG-7500 is administered orally once daily” NCT06011317 ↗ |